[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356649-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-356649-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","efficacy-and-safety-of-a-novel-clearhemograsper-for-gastric-endoscopic-submucosal-dissection-a-prospective-randomized-controlled-trial","Efficacy and safety of a novel ClearHemograsper for gastric endoscopic submucosal dissection: A prospective randomized controlled trial","","Endoscopic submucosal dissection (ESD) for gastric neoplasms requires effective hemostasis to ensure safety and procedural success. This single-center, prospective, randomized controlled trial compared a newly developed hemostatic device (ClearHemograsper) with the established Coagrasper in 157 patients treated from December 2022 to November 2023. No significant differences were found in bleeding control time or total procedure time. En bloc resection was achieved for all lesions, and early or delayed adverse events did not differ significantly. All events were managed with endoscopic hemostasis, supporting comparable efficacy and safety.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/efficacy-and-safety-of-a-novel-clearhemograsper-for-gastric-endoscopic-submucosal-dissection-a-prospective-randomized-controlled-trial/356649/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/efficacy-and-safety-of-a-novel-clearhemograsper-for-gastric-endoscopic-submucosal-dissection-a-prospective-randomized-controlled-trial/356649.png","ImageObject",300,407,{"name":42,"@type":43},"Riley West","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What was the purpose of the study?","Question",{"text":63,"@type":64},"To evaluate the efficacy and safety of the newly developed hemostatic device ClearHemograsper compared with Coagrasper during gastric ESD.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were patients assigned in the trial?",{"text":68,"@type":64},"Patients who underwent ESD for gastric neoplasms between December 2022 and November 2023 were randomly assigned to either the ClearHemograsper group or the Coagrasper group.",{"name":70,"@type":61,"acceptedAnswer":71},"Did ClearHemograsper improve bleeding control time compared with Coagrasper?",{"text":72,"@type":64},"No statistically significant differences were found in bleeding control time between the two groups.",{"name":74,"@type":61,"acceptedAnswer":75},"How were adverse events handled?",{"text":76,"@type":64},"Adverse events, including early and delayed bleeding, were effectively managed through endoscopic hemostasis.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},356649,1790159017,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,114,119,124,127,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},7,40,"healthcare",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},8,"Research & Report",30,"research-report",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},9,"Religion & Spirituality",20,"religion-spirituality",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":122,"slug":126},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":120,"language":143,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":12,"update_tm":147,"read_time":148},1099523885074,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nEfficacy and safety of a novel ClearHemograsper for gastric endoscopic submucosal dissection:  \nA prospective randomized controlled trial  \nJin Hee Noh, Do Hoon Kim􀀍, Hee Kyong Na, Ji Yong Ahn, Jeong Hoon Lee, Kee Wook Jung, Kee Don Choi, Ho June Song, Gin Hyug Lee & Hwoon-Yong Jung  \nEndoscopic submucosal dissection (ESD) has become a widely performed procedure for the management of gastric neoplasms. Effective hemostasis during ESD is critical for procedural success and patient safety. This study aimed to evaluate the efficacy and safety of a newly developed hemostatic device, ClearHemograsper, in gastric ESD. Patients who underwent ESD for gastric neoplasms between December 2022 and November 2023 were enrolled and randomly assigned to either the ClearHemograsper group or the Coagrasper group. We conducted a comprehensive analysis of clinicopathologic features and endoscopic treatment outcomes. A total of 157 patients, comprising 80 patients in the ClearHemograsper group and 77 patients in the Coagrasper group, were included in the final analysis. Analyses found no statistically significant differences in the bleeding control time (3.2 ± 2.9 vs. 3.5 ± 2.7 min, 95% Confidence interval, -1.227 to 0.526; p = 0.430) and total procedure time (15.2 ± 11.8 vs. 15.5 ± 10.4 min, p = 0.846) between the groups. En bloc resection was successfully performed for all lesions in both groups. Adverse events, including early bleeding (10.0% vs. 3.9%) within 48 h post-procedure and delayed bleeding (0.0% vs. 1.3%), showed no significant differences between the two groups (p = 0.211). All adverse events were effectively managed through endoscopichemostasis. Novel ClearHemograsper demonstrates comparable efficacy and safety toCoagrasper, with preliminary evidence suggesting non-inferior or potentially superior hemostatic performance. These results demonstrate the comparable performance of domestic products in the Korean market, where overseas products occupy the majority of the device market share.  \nKeywords Endoscopic submucosal dissection, Gastric neoplasms, Hemostatic Forceps  \nGastric cancer is the third most frequently diagnosed cancer and the fourth primary cause of cancer mortality in South Korea, according to the Global Cancer Statistics (GLOBOCAN 2022)1. The National Cancer Screening Program for Gastric Cancer has increased the early detection rate of gastric cancer from 54.6% in 2009 to 66.0% in 2021, leading to more patients being eligible for endoscopic resection2. Endoscopic submucosal dissection (ESD) is widely accepted as the standard treatment for gastric neoplasms, including early gastric cancer and gastric dysplasia.  \nBleeding is a common complication of ESD, occurring immediately during the procedure in approximately 22.6% to 90.6% of cases, with delayed bleeding reported in approximately 5% of cases3. Adequate hemostasis during ESD is critical to ensuring the patient’s hemodynamic stability and providing a clear view for the endoscopist, affecting the success and complication rates of the procedure4. Hemostasis provides a relatively quick and easy approach for managing bleeding sites or exposed vessels, with contact methods showing higher success rates compared to non-contact methods5. Hemostasis using hemostatic forceps is classified as a contact method. While minor bleeding from small blood vessels can typically be controlled using the ESD knife tip, large blood vessels or those with pulsation require hemostasis with specialized forceps.  \nDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea. 􀀍 email: [dohoon.md@gmail.com](dohoon.md@gmail.com)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nThe Coagrasper, a hemostatic forceps manufactured by Olympus Medical, has been used almost exclusively since its approval in Korea in 2","cbCaitmjatGXSFeW","https://ap.wps.com/l/cbCaitmjatGXSFeW","pdf",1590781,"English","# Methods\n## Study design and population","[{\"question\":\"What was the purpose of the study?\",\"answer\":\"To evaluate the efficacy and safety of the newly developed hemostatic device ClearHemograsper compared with Coagrasper during gastric ESD.\"},{\"question\":\"How were patients assigned in the trial?\",\"answer\":\"Patients who underwent ESD for gastric neoplasms between December 2022 and November 2023 were randomly assigned to either the ClearHemograsper group or the Coagrasper group.\"},{\"question\":\"Did ClearHemograsper improve bleeding control time compared with Coagrasper?\",\"answer\":\"No statistically significant differences were found in bleeding control time between the two groups.\"},{\"question\":\"How were adverse events handled?\",\"answer\":\"Adverse events, including early and delayed bleeding, were effectively managed through endoscopic hemostasis.\"}]","Efficacy and safety of a novel ClearHemograsper for gastric endoscopic submucosal dissection: A prospective randomized controlled trial | PDF",1790126589,23]